Samsung Bioepis, Boryung Partner on Bone Disorder Biosimilar ‘Exbrick’

[Kim Saemi, Edaily Reporter] Samsung Bioepis announced on July 2 that it has signed a domestic partnership agreement with Boryung for the sales of ‘Exbrick,’ a biosimilar referencing Xgeva, a treatment for bone disorders.

CI of Samsung Bioepis and Boryung (Source: Both Companies) Under the agreement, Samsung Bioepis, as the developer, will be responsible for manufacturing and supplying Exbrick, while Boryung will take charge of exclusive domestic sales and marketing.

Xgeva, developed by Amgen, is indicated for the prevention of skeletal-related events (SREs) in patients with bone metastases and for the treatment of giant cell tumor of bone.